Autopsy report · NCT00306150
Efficacy and Safety of Aprotinin on Transfusion Requirements in Patients Undergoing Radical or Total Cystectomy
Cause of deathNo reason given
Life of this trial
- Registered 3 months after it had already started.
- Ran for about 1 year 3 months before it stopped.
- 57 participants enrolled.
- No results are posted on the registry.
Vital statistics
- Status
- Terminated
- Phase
- Phase 3
- Sponsor
- Bayer
- Sponsor type
- Industry
- Conditions
- Blood Loss, Surgical; Postoperative Hemorrhage
- Interventions
- Trasylol (Aprotinin, BAYA0128); Placebo
- Participants
- 57
- Sites
- 37
- Countries
- Belgium, France, Germany, Netherlands, Sweden, United Kingdom, United States
Look deeper
- The official registry record (the source of truth)
- Record history: every change the sponsor made
- Open it in the database
Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.